

IMI: Exane BNP upgrades to outperform from neutral. Smiths Group: Exane BNP upgrades to outperform from neutral. RBS: Shore Capital upgrades to ho...


Capita: Bank of America-Merrill Lynch downgrades to neutral from buy. Carnival: Credit Suisse keeps neutral rating and 2,285p target; Morgan Stanley...


AIM-listed bioscience firm Abcam is on track to meet profit forecasts for the full-year after first-half revenues rose by 13.5% in the six months to D...


A non-executive director of both broadband provider TalkTalk and mobile phone seller Carphone Warehouse has made a double purchase, phoning in orders ...


Abcam initially produced primary antibodies, tools used in genetic research. Four fifths of its products go into laboratories and other research facil...


AIM-listed bioscience firm Abcam hiked its final dividend by 30% as it reported a 25% increase in profits in the year ended 30 June. The protein rese...


Fund manager Ashmore is set to issue full-year results on Tuesday. Singer Capital Markets is a fan of the shares and expects that with positive return...


Bioscience firm Abcam has acquired US-based mitochondrial research tools provider MitoSciences for a total consideration of $6m (£3.7m), as it attempt...